Isocitrate Dehydrogenase Mutations Confer Dasatinib Hypersensitivity and SRC Dependence in Intrahepatic Cholangiocarcinoma.

Autor: Saha SK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Gordan JD; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Kleinstiver BP; Molecular Pathology Unit, Center for Cancer Research, and Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts., Vu P; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Najem MS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Yeo JC; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Shi L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Kato Y; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Levin RS; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California., Webber JT; Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California., Damon LJ; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Egan RK; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Greninger P; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., McDermott U; Wellcome Trust Sanger Institute, Hinxton, UK., Garnett MJ; Wellcome Trust Sanger Institute, Hinxton, UK., Jenkins RL; Department of Transplantation, Lahey Hospital and Medical Center, Burlington, Massachusetts., Rieger-Christ KM; Department of Translational Research, Lahey Hospital and Medical Center, Burlington, Massachusetts., Sullivan TB; Department of Translational Research, Lahey Hospital and Medical Center, Burlington, Massachusetts., Hezel AF; University of Rochester School of Medicine, Rochester, New York., Liss AS; Department of Surgery and the Andrew L. Warshaw, MD, Institute for Pancreatic Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts., Mizukami Y; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. Center for Clinical and Biomedical Research, Sapporo Higashi Tokushukai Hospital, Sapporo, Hokkaido, Japan., Goyal L; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Ferrone CR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Zhu AX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts., Joung JK; Molecular Pathology Unit, Center for Cancer Research, and Center for Computational and Integrative Biology, Massachusetts General Hospital, Charlestown, Massachusetts. Department of Pathology, Harvard Medical School, Boston, Massachusetts., Shokat KM; Department of Cellular and Molecular Pharmacology, University of California, San Francisco, San Francisco, California. Howard Hughes Medical Institute, University of California, San Francisco, San Francisco, California., Benes CH; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. nelbardeesy@partners.org cbenes@mgh.harvard.edu., Bardeesy N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts. nelbardeesy@partners.org cbenes@mgh.harvard.edu.

Publikováno v: Cancer discovery [Cancer Discov] 2016 Jul; Vol. 6 (7), pp. 727-39. Date of Electronic Publication: 2016 May 26.

Mutant IDH inhibits HNF-4α to block hepatocyte differentiation and promote biliary cancer.

Autor: Saha SK; 1] Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA [2]., Parachoniak CA; 1] Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA [2]., Ghanta KS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA., Fitamant J; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA., Ross KN; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA., Najem MS; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA., Gurumurthy S; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA., Akbay EA; Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA., Sia D; 1] HCC Translational Research Laboratory, Barcelona-Clínic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Catalonia 08036, Spain [2] Mount Sinai Liver Cancer Program, Division of Liver Diseases, Dept of Medicine. Icahn School of Medicine at Mount Sinai, New York 10029, USA [3] Gastrointestinal Surgery and Liver Transplantation Unit, National Cancer Institute, and Department of Experimental Oncology, Milan 20133, Italy., Cornella H; HCC Translational Research Laboratory, Barcelona-Clínic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Catalonia 08036, Spain., Miltiadous O; Mount Sinai Liver Cancer Program, Division of Liver Diseases, Dept of Medicine. Icahn School of Medicine at Mount Sinai, New York 10029, USA., Walesky C; Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160, USA., Deshpande V; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA., Zhu AX; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA., Hezel AF; University of Rochester Medical Center, Rochester, New York 14642, USA., Yen KE; Agios Pharmaceuticals, Cambridge, Massachusetts 02139, USA., Straley KS; Agios Pharmaceuticals, Cambridge, Massachusetts 02139, USA., Travins J; Agios Pharmaceuticals, Cambridge, Massachusetts 02139, USA., Popovici-Muller J; Agios Pharmaceuticals, Cambridge, Massachusetts 02139, USA., Gliser C; Agios Pharmaceuticals, Cambridge, Massachusetts 02139, USA., Ferrone CR; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA., Apte U; Department of Pharmacology, Toxicology and Therapeutics, University of Kansas Medical Center, Kansas City, Kansas 66160, USA., Llovet JM; 1] HCC Translational Research Laboratory, Barcelona-Clínic Liver Cancer Group, Liver Unit, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Hospital Clínic, University of Barcelona, Catalonia 08036, Spain [2] Mount Sinai Liver Cancer Program, Division of Liver Diseases, Dept of Medicine. Icahn School of Medicine at Mount Sinai, New York 10029, USA [3] Institució Catalana de Recerca i Estudis Avançats, Barcelona, Catalonia 08010, Spain [4] University of Barcelona, Catalonia 08036, Spain., Wong KK; Department of Medical Oncology, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115, USA., Ramaswamy S; 1] Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA [2] Broad Institute of Harvard and MIT, Cambridge, Massachusetts 02142, USA., Bardeesy N; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts 02114, USA.

Publikováno v: Nature [Nature] 2014 Sep 04; Vol. 513 (7516), pp. 110-4. Date of Electronic Publication: 2014 Jul 02.